| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PTP4A2 |
| Uniprot No | Q12974 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-167aa |
| 氨基酸序列 | MRGSHHHHHH GMASMTGGQQ MGRDLYDDDD KDRWGSMNRP APVEISYENM RFLITHNPTN ATLNKFTEEL KKYGVTTLVR VCDATYDKAP VEKEGIHVLD WPFDDGAPPP NQIVDDWLNL LKTKFREEPG CCVAVHCVAG LGRAPVLVAL ALIECGMKYE DAVQFIRQKR RGAFNSKQLL YLEKYRPKMR LRFRDTNGHC CVQ |
| 预测分子量 | 23 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PTP4A2重组蛋白的3篇参考文献及其摘要概括(文献信息为模拟示例，实际需根据真实文献调整)：
---
1. **文献名称**: *PTP4A2 promotes tumor metastasis through regulation of EGFR signaling pathways*
**作者**: Zhang Y, et al. (2015)
**摘要**: 本研究利用大肠杆菌表达系统成功获得高纯度重组PTP4A2蛋白，并证实其通过调控EGFR下游信号通路增强癌细胞迁移和侵袭能力，提示其作为肿瘤治疗靶点的潜力。
---
2. **文献名称**: *Structural and functional characterization of recombinant PTP4A2 phosphatase*
**作者**: Lee S, et al. (2018)
**摘要**: 通过哺乳动物细胞表达重组PTP4A2蛋白，解析其三维结构及催化活性关键位点，发现其特异性去磷酸化MAPK通路中的靶蛋白，为设计选择性抑制剂提供结构基础。
---
3. **文献名称**: *PTP4A2 interacts with β-catenin to drive chemoresistance in colorectal cancer*
**作者**: Chen X, et al. (2020)
**摘要**: 采用昆虫细胞表达系统制备重组PTP4A2蛋白，结合蛋白质互作筛选，揭示其通过稳定β-catenin促进结直肠癌细胞对5-FU化疗的耐药性，机制涉及Wnt信号通路异常激活。
---
**注**：以上文献信息为示例性质，实际研究中建议通过PubMed或Web of Science检索关键词“PTP4A2 recombinant”“PRL-2 protein”等获取真实文献。
PTP4A2. also known as protein tyrosine phosphatase type IVA 2 or PRL-2 (phosphatase of regenerating liver-2), is a member of the PTP4A subfamily of dual-specificity phosphatases. This protein family, comprising PTP4A1. PTP4A2. and PTP4A3 (PRL-1 to PRL-3), is characterized by a conserved catalytic domain and a C-terminal prenylation motif (CAAX box) that facilitates membrane association. PTP4A2 is implicated in cellular signaling pathways regulating proliferation, migration, and metastasis, though its precise biological roles remain under investigation.
Structurally, PTP4A2 lacks traditional tyrosine phosphatase activity but exhibits phosphatase activity toward phosphoinositides and phosphoserine/threonine residues. It localizes to cellular membranes, including endosomes and the Golgi apparatus, due to post-translational prenylation. This subcellular positioning suggests roles in vesicle trafficking, cytoskeletal dynamics, or receptor signaling. Overexpression of PTP4A2 has been observed in multiple cancers, including colorectal, breast, and lung carcinomas, where it correlates with advanced disease stages and poor prognosis. Experimental models indicate it promotes oncogenic transformation, cell invasion, and resistance to apoptosis, potentially through interactions with pathways like MAPK/ERK or PI3K/Akt.
Recombinant PTP4A2 protein is commonly produced in bacterial or mammalian expression systems for functional studies. Its applications include enzymatic activity assays, identification of binding partners via pull-down experiments, and structure-function analyses to map catalytic or regulatory domains. Researchers also utilize recombinant PTP4A2 in drug discovery screens targeting phosphatases involved in cancer progression. However, challenges persist in elucidating its physiological substrates and context-dependent roles, as conflicting reports describe both pro-metastatic and tumor-suppressive effects in different cellular environments. Ongoing research aims to clarify these mechanisms and explore therapeutic targeting opportunities.
×
